Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Simulations Plus Inc
(NQ:
SLP
)
36.83
+0.35 (+0.96%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Simulations Plus Inc
< Previous
1
2
3
4
5
6
7
Next >
Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment
August 15, 2023
From
Simulations Plus, Inc.
Via
Business Wire
Simulations Plus Releases ADMET Predictor® 11
July 13, 2023
From
Simulations Plus, Inc.
Via
Business Wire
Recap: Simulations Plus Q3 Earnings
July 06, 2023
Via
Benzinga
Simulations Plus's Earnings: A Preview
July 05, 2023
Via
Benzinga
Preview: Simulations Plus's Earnings
April 04, 2023
Via
Benzinga
Simulations An Attractive Vehicle For Investors Seeking Exposure To Biotech Innovation Themes, Analyst Says
July 07, 2023
Oppenheimer analyst Francois Brisebois reiterated an Outperform rating on Simulations Plus, Inc. (NASDAQ: SLP) with a
Via
Benzinga
Costco, AZZ And 3 Stocks To Watch Heading Into Friday
July 07, 2023
With U.S. stock futures trading slightly lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results
July 06, 2023
From
Simulations Plus, Inc.
Via
Business Wire
Simulations Plus Announces Third Quarter Fiscal Year 2023 Earnings and Conference Call Date
June 21, 2023
From
Simulations Plus, Inc.
Via
Business Wire
Simulations Plus Is High-Growth Investment Opportunity In The Wake Of Immunetrics Acquisition: Analyst
June 21, 2023
Oppenheimer analyst Francois Brisebois reiterated an Outperform rating on the shares of Simulations Plus, Inc. (NASDAQ: SLP),
Via
Benzinga
Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities
June 20, 2023
From
Simulations Plus, Inc.
Via
Business Wire
7 Stocks Under $50 to Buy (and Never Sell)
May 29, 2023
Although you usually get what you pay for, these best affordable stocks to invest in punch above their weight class.
Via
InvestorPlace
Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
May 10, 2023
From
Simulations Plus, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2023
May 09, 2023
Via
Benzinga
Roblox And 3 Other Stocks Insiders Are Selling
April 28, 2023
The Nasdaq Composite closed sharply higher on Thursday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
April 18, 2023
From
Simulations Plus, Inc.
Via
Business Wire
Simulations Plus Reports Second Quarter Fiscal 2023 Financial Results
April 05, 2023
From
Simulations Plus, Inc.
Via
Business Wire
MIDD+ 2023 Panelists Discuss How to Increase Gender Equity for Women in Science
March 30, 2023
From
Simulations Plus, Inc.
Via
Business Wire
Simulations Plus Sets Date for Second Quarter Fiscal Year 2023 Earnings Release and Conference Call
March 21, 2023
From
Simulations Plus, Inc.
Via
Business Wire
Simulations Plus to Present at Sidoti March Small-Cap Conference
March 16, 2023
From
Simulations Plus, Inc.
Via
Business Wire
Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology
March 28, 2023
From
Simulations Plus, Inc.
Via
Business Wire
Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
March 15, 2023
From
Simulations Plus, Inc.
Via
Business Wire
Lixoft Adds New Data Formatting and Reporting Modules to MonolixSuite™ in Version 2023R1
March 09, 2023
From
Simulations Plus, Inc.
Via
Business Wire
Simulations Plus to Present at Oppenheimer 33rd Annual Healthcare Conference
March 07, 2023
From
Simulations Plus, Inc.
Via
Business Wire
Simulations Plus to Present at Raymond James 44th Annual Institutional Investors Conference
February 28, 2023
From
Simulations Plus, Inc.
Via
Business Wire
Simulations Plus and Global Agrochemicals Leader to Collaborate on Machine Learning Models
February 16, 2023
From
Simulations Plus, Inc.
Via
Business Wire
Simulations Plus Releases Redesigned NAFLDsym® QSP Software Tool
February 09, 2023
From
Simulations Plus, Inc.
Via
Business Wire
Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure
January 12, 2023
From
Simulations Plus, Inc.
Via
Business Wire
Simulations Plus Executes $20 Million Accelerated Share Repurchase Agreement
January 11, 2023
From
Simulations Plus, Inc.
Via
Business Wire
Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 05, 2023
Gainers Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares surged 179.3% to $2.4585 after the company announced that it has entered into a license agreement for the development and commercialization...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.